SPRIND (Germany’s Federal Agency for Disruptive Innovation): A Quantum Shift for New Antiviral Agents

- aims to actively contribute to advancing the development of antivirals for the treatment of infections. SPRIND is looking for new approaches that fundamentally change the development of antiviral agents. The result may expand the repertoire for combating viruses or may be a technology that can be adapted to the respective situation using new drug candidates, assays, platforms, etc. We are looking for solutions that combat human pathogenic viruses, preferably newly emerging viruses with pandemic potential. Ideas should ideally result in antiviral agents for more than one virus family if possible. Applicants are expected to develop their projects up to a proof-of-concept within the framework of the Challenge.

Funding: stage 1- up to 700.000 € per team. Teams are eligible to apply if their primary residence is in the European Economic Area (EEA). Yet, teams may also join in a cooperation with a team based in the EEA.

https://www.sprind.org/en/challenges/antiviral